Prof Sagar Lonial speaks to ecancer about his study regarding iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in relapsed/refractory multiple myeloma patients.
Initially, he mentions the background of the study. Prof Lonial then discusses the findings of the study.
He concludes, by talking about how the results from this study can impact the future treatment of RRMM.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.